pemoline has been researched along with Atrophy in 1 studies
Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.
pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
Excerpt | Relevance | Reference |
---|---|---|
"Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions." | 2.48 | Fatigue in multiple sclerosis - a brief review. ( Constantinescu, CS; Gran, B; Induruwa, I, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Induruwa, I | 1 |
Constantinescu, CS | 1 |
Gran, B | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093] | 40 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial[NCT02607020] | 100 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for pemoline and Atrophy
Article | Year |
---|---|
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |